T-DM1-resistant cells gain high invasive activity via EGFR and integrin cooperated pathways

References

• Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. 2010;21(1):5–13. doi:10.1021/bc9002019.
   PubMed Web of Science ®Google Scholar
• Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RVJ, Lutz RJ, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280–9290. doi:10.1158/0008-5472.CAN-08-1776.
   PubMed Web of Science ®Google Scholar
• Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(19):2078–2099. doi:10.1200/JCO.2013.54.0948.
   PubMed Web of Science ®Google Scholar
• Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson HA, Gunter B, Audette CA, Guta M, Pinkas J, et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther. 2012;11(5):1133–1142. doi:10.1158/1535-7163.MCT-11-0727.
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, ElZarrad KM, Hirsch DS, Wu JW. Antibody-drug conjugates as therapeutic agents in oncology: overview and perspectives. In: Atta-ur-Rahman M, Choudhary I, editors. Frontiers in anti-cancer drug discovery. Oak Park (IL): Bentham Science Publishers; 2013. p. 139–189.
   Google Scholar
• Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol. 2009;13(3):235–244. doi:10.1016/j.cbpa.2009.03.023.
   PubMed Web of Science ®Google Scholar
• Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr Med Res Opin. 2013;29(4):405–414. doi:10.1185/03007995.2013.775113.
   PubMed Web of Science ®Google Scholar
• Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16(2):209. doi:10.1186/s13058-014-0492-9.
   PubMed Web of Science ®Google Scholar
• Loganzo F, Tan X, Sung M, Jin G, Myers JS, Melamud E, Wang F, Diesl V, Follettie MT, Musto S, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015;14(4):952–963. doi:10.1158/1535-7163.MCT-14-0862.
   PubMed Web of Science ®Google Scholar
• Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, Tamura T, Nishio K, Nakagawa K, Tsurutani J. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer. 2017;141(8):1682–1689. doi:10.1002/ijc.30870.
   PubMed Web of Science ®Google Scholar
• Lewis Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, Andre F, Burris HA, 3rd, Albain KS, Harbeck N. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res. 2014;20(2):456–468. doi:10.1158/1078-0432.CCR-13-0358.
   PubMed Web of Science ®Google Scholar
• Sabbaghi M, Gil-Gómez G, Guardia C, Servitja S, Arpí O, García-Alonso S, Menendez S, Arumi-Uria M, Serrano L, Salido M, et al. Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer. Clin Cancer Res. 2017;23(22):7006–7019. doi:10.1158/1078-0432.CCR-17-0696.
   PubMed Web of Science ®Google Scholar
• Ríos-Luci C, García-Alonso S, Díaz-Rodríguez E, Nadal-Serrano M, Arribas J, Ocaña A, Pandiella A. Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity. Cancer Res. 2017;77(17):4639–4651. doi:10.1158/0008-5472.CAN-16-3127.
   PubMed Web of Science ®Google Scholar
• Sung M, Tan X, Lu B, Golas J, Hosselet C, Wang F, Tylaska L, King L, Zhou D, Dushin R, et al. Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1). Mol Cancer Ther. 2018;17(1):243–253. doi:10.1158/1535-7163.MCT-17-0403.
   PubMed Web of Science ®Google Scholar
• Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2(2):91–100. doi:10.1038/nrc727.
   PubMed Web of Science ®Google Scholar
• Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9–22. doi:10.1038/nrc2748.
   PubMed Web of Science ®Google Scholar
• Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673–687.
   PubMed Web of Science ®Google Scholar
• Huttenlocher A, Horwitz AR. Integrins in cell migration. Cold Spring Harb Perspect Biol. 2011;3(9):a005074. doi:10.1101/cshperspect.a005074.
   PubMed Web of Science ®Google Scholar
• Hirsch DS, Wu WJ. Cdc42: an effector and regulator of ErbB1 as a strategic target in breast cancer therapy. Expert Rev Anticancer Ther. 2007;7(2):147–157. doi:10.1586/14737140.7.2.147.
   PubMed Web of Science ®Google Scholar
• Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009;21(2):177–184. doi:10.1016/j.ceb.2008.12.010.
   PubMed Web of Science ®Google Scholar
• Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K, Isola J. Characterization of a novel cell line established from a patient with herceptin-resistant breast cancer. Mol Cancer Ther. 2004;3(12):1585–1592.
   PubMed Web of Science ®Google Scholar
• Oropesa-Ávila M, Fernández-Vega A, de la Mata M, Maraver JG, Cordero MD, Cotán D, de Miguel M, Calero CP, Paz MV, Pavón AD. Apoptotic microtubules delimit an active caspase free area in the cellular cortex during the execution phase of apoptosis. Cell Death Dis. 2013;4:e527. doi:10.1038/cddis.2013.58.
   PubMed Web of Science ®Google Scholar
• Loganzo F, Sung M, Gerber HP. Mechanisms of resistance to antibody-drug conjugates. Mol Cancer Ther. 2016;15(12):2825–2834. doi:10.1158/1535-7163.MCT-16-0408.
   PubMed Web of Science ®Google Scholar
• Murphy DA, Courtneidge SA. The ‘ins’ and ‘outs’ of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol. 2011;12(7):413–426. doi:10.1038/nrm3141.
   PubMed Web of Science ®Google Scholar
• Mould AP, Akiyama SK, Humphries MJ. The inhibitory anti-beta 1 integrin monoclonal antibody 13 recognizes an epitope that is attenuated by ligand occupancy. Evidence for allosteric inhibition of integrin function. J Biol Chem. 1996;271(34):20365–20374.
   PubMed Web of Science ®Google Scholar
• Yamada KM, Kennedy DW, Yamada SS, Gralnick H, Chen WT, Akiyama SK. Monoclonal antibody and synthetic peptide inhibits of human tumor cell migration. Cancer Res. 1990;50(15):4485–4496.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182.
   PubMed Web of Science ®Google Scholar
• Crouch S, Spidel CS, Lindsey JS. HGF and ligation of αvβ5 integrin induce a novel, cancer cell-specific gene expression required for cell scattering. Exp Cell Res. 2004;292(2):274–287.
   PubMed Web of Science ®Google Scholar
• Brooks PC, Klemke RL, Schӧn S, Lewis JM, Schwartz MA, Cheresh DA. Insulin-like growth factor receptor cooperates with integrin αvβ5 to promote tumor cell dissemination in vivo. J Clin Invest. 1997;99(6):1390–1398. doi:10.1172/JCI119298.
   PubMed Web of Science ®Google Scholar
• Klemke RL, Yebra M, Bayna EM, Cheresh DA. Receptor tyrosine kinase signaling required for integrin αvβ5-directed cell motility but not adhesion to vitronectin. J Cell Biol. 1994;127(3):859–866.
   PubMed Web of Science ®Google Scholar
• Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, et al. An integrin β3-KRAS-RalB complex drives tumor stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014;16(5):457–468. doi:10.1038/ncb2953.
   PubMed Web of Science ®Google Scholar
• Steeg PS. Targeting metastasis. Nat Rev Cancer. 2016;16:201–218. doi:10.1038/nrc.2016.25.
   PubMed Web of Science ®Google Scholar
• Chen KG, Sikic BI. Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res. 2012;18(7):1863–1869. doi:10.1158/1078-0432.CCR-11-1590.
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92(16):1295–1302.
   PubMed Web of Science ®Google Scholar
• Munoz M, Henderson M, Haber M, Norris M. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life. 2007;59(12):752–757. doi:10.1080/15216540701736285.
   PubMed Web of Science ®Google Scholar
• Dos Santos PB, Zanetti JS, Ribeiro-Silva A, Beltrão EI. Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study. Diagn Pathol. 2012;7:104. doi:10.1186/1746-1596-7-104.
   PubMed Web of Science ®Google Scholar
• Hu Z, Gao S, Gao J, Hou R, Liu C, Liu J, Liu D, Zhang S, Lin B. Elevated levels of Lewis y and integrin α5β1 correlate with chemotherapeutic drug resistance in epithelial ovarian carcinoma. Int J Mol Sci. 2012;13(12):15588–15600. doi:10.3390/ijms131215588.
   PubMed Web of Science ®Google Scholar
• Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ, Bissell MJ. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res. 2006;66(3):1526–1535. doi:10.1158/0008-5472.CAN-05-3071.
   PubMed Web of Science ®Google Scholar
• Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, Buck CA. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res. 1990;50(20):6757–6764.
   PubMed Web of Science ®Google Scholar
• Horioka K, Ohuchida K, Sada M, Zheng B, Moriyama T, Fujita H, Manabe T, Ohtsuka T, Shimamoto M, Miyazaki T, et al. Suppression of CD51 in pancreatic stellate cells inhibits tumor growth by reducing stroma and altering tumor-stromal interaction in pancreatic cancer. Int J Oncol. 2016;48(4):1499–1508. doi:10.3892/ijo.2016.3374.
   PubMed Web of Science ®Google Scholar
• Waisberg J, de Souza Viana L, Affonso Junior RJ, Silva SR, Denadai MV, Margeotto FB, de Souza CS, Matos D. Overexpression of the ITGAV gene is associated with progression and spread of colorectal cancer. Anticancer Res. 2014;34(10):5599–5608.
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Kovanda AK, Melchardt T, Bartsch R, Hainfellner JA, Sipos B, Schittenhelm J, Zielinski CC, Widhalm G, Dieckmann K, et al. αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer. Clin Exp Metastasis. 2014;31(7):841–851. doi:10.1007/s10585-014-9675-0.
   PubMed Web of Science ®Google Scholar
• Vogetseder A, Thies S, Ingold B, Roth P, Weller M, Schraml P, Goodman SL, Moch H. αv-integrin isoform expression in primary human tumors and brain metastases. Int J Cancer. 2013;133(10):2362–2371. doi:10.1002/ijc.28267.
   PubMed Web of Science ®Google Scholar
• Li F, Liu Y, Kan X, Li Y, Liu M, Lu JG. Elevated expression of integrin αv and β5 subunit in laryngeal squamous-cell carcinoma associated with lymphatic metastasis and angiogenesis. Pathol Res Pract. 2013;209(2):105–109. doi:10.1016/j.prp.2012.11.001.
   PubMed Web of Science ®Google Scholar
• van der Horst G, Bos L, van der Mark M, Cheung H, Heckmann B, Clément-Lacroix P, Lorenzon G, Pelger RC, Bevers RF, van der Pluijm G. Targeting of alpha-v integrins reduces malignancy of bladder carcinoma. PLoS One. 2014;9(9):e108464. doi:10.1371/journal.pone.0108464.
   PubMed Web of Science ®Google Scholar
• Liu H, Radisky DC, Yang D, Xu D, Radisky ES, Bissell MJ, Bishop JM. MYC suppresses cancer metastasis by direct transcriptional silencing of αv and β3 integrin subunits. Nat Cell Biol. 2012;14(6):567–574. doi:10.1038/ncb2491.
   PubMed Web of Science ®Google Scholar
• van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Pelger RC, van der Pluijm G. Integrin αv expression is required for the acquisition of a metastatic stem/progenitor cell phenotype in human prostate cancer. Am J Pathol. 2011;179(5):2559–2568. doi:10.1016/j.ajpath.2011.07.011.
   PubMed Web of Science ®Google Scholar
• Nemeth JA, Nakada MT, Trikha M, Lang Z, Gordon MS, Jayson GC, Corringham R, Prabhakar U, Davis HM, Bechman RA. Alpha-v integrins as therapeutic targets in oncology. Cancer Invest. 2007;25(7):632–646. doi:10.1080/07357900701522638.
   PubMed Web of Science ®Google Scholar
• Yan H, Endo Y, Shen Y, Rotstein D, Dokmanovic M, Mohan N, Mukhopadhyay P, Gao B, Pacher P, Wu WJ. Ado-trastuzumab emtansine targets hepatocytes via human epidermal growth factor receptor 2 to induce hepatotoxicity. Mol Cancer Ther. 2016;15(3):480–490. doi:10.1158/1535-7163.MCT-15-0580.
   PubMed Web of Science ®Google Scholar
• Hirsh DS, Shen Y, Wu WJ. Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of cdc42. Cancer Res. 2006;66(7):3523–3530. doi:10.1158/0008-5472.CAN-05-1547.
   PubMed Web of Science ®Google Scholar